Get the Stockscreener App
0.621
9.62%
-0.0661
Adicet Bio Inc stock is traded at $0.621, with a volume of 2.37M.
It is down -9.62% in the last 24 hours and down -9.05% over the past month.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
See More
Previous Close:
$0.6871
Open:
$0.68
24h Volume:
2.37M
Relative Volume:
4.61
Market Cap:
$51.36M
Revenue:
$38.70M
Net Income/Loss:
$-117.88M
P/E Ratio:
-0.3653
EPS:
-1.7
Net Cash Flow:
$-92.84M
1W Performance:
-7.40%
1M Performance:
-9.05%
6M Performance:
-35.66%
1Y Performance:
-53.31%
1-Day Range:
$0.621
$0.6899
1-Week Range:
$0.621
$0.734
52-Week Range:
$0.4471
$1.6399
Adicet Bio Inc Stock (ACET) Company Profile
Name
Adicet Bio Inc
Sector
Industry
Phone
617-482-2333
Address
131 DARTMOUTH STREET, BOSTON
Compare ACET with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
0.621 | 57.97M | 38.70M | -117.88M | -92.84M | -1.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-24 | Resumed | Guggenheim | Buy |
| Sep-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-27-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Mar-31-22 | Initiated | SMBC Nikko | Outperform |
| Mar-08-22 | Initiated | Truist | Buy |
| Mar-04-22 | Initiated | Jefferies | Buy |
| May-18-21 | Initiated | BTIG Research | Buy |
| Apr-23-21 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Canaccord Genuity | Buy |
| Apr-08-21 | Initiated | Guggenheim | Buy |
| Nov-04-20 | Initiated | B. Riley Securities | Buy |
| Oct-27-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-16-20 | Initiated | Wedbush | Outperform |
View All
Adicet Bio Inc Stock (ACET) Latest News
Layoff Tracker: Bicycle, Tune, Iovance, Precision Downsize to Conserve Cash - BioSpace
MaxCyte signs platform license agreement with Adicet Bio - MSN
Adicet Bio: Strategic Advancements and Financial Prudence Drive Analyst's Buy Rating - AInvest
Adicet Bio: Strategic Advancements and Financial Prudence Drive Buy Rating - TipRanks
Adicet Bio (ACET) Q2 Loss Widens 3% - AOL.com
Adicet Bio reports Q2 EPS (34c), consensus (30c) - TipRanks
Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates - Business Wire
Adicet Bio Reports Q2 2025 Financial Results - TipRanks
Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference - BioSpace
MaxCyte Partners with Adicet Bio for Gamma Delta T Cell Therapy Platform License Agreement - AInvest
MaxCyte Inks Strategic Platform License with Adicet Bio, Entitled to Licensing Fees and Revenue - AInvest
Maxcyte signs platform license agreement with Adicet Bio - MarketScreener
MaxCyte Signs Platform License Agreement with Adicet Bio - The Manila Times
MaxCyte, Adicet Bio Sign Strategic Platform License Agreement - AInvest
MaxCyte Expands Cell Therapy Reach: Strategic License Deal Powers Adicet's Cancer Treatment Innovation - Stock Titan
What are Adicet Bio Inc. company’s key revenue driversAchieve rapid portfolio growth with smart picks - Jammu Links News
Is it the right time to buy Adicet Bio Inc. stockMaximize gains with proven stock analysis - Jammu Links News
What markets is Adicet Bio Inc. expanding into Is AMZE stock a good long term investment optionTriple-digit return opportunities - Jammu Links News
What drives Adicet Bio Inc. stock priceBuild a diversified portfolio for steady growth - Jammu Links News
Why is Adicet Bio Inc. stock attracting strong analyst attentionMaximize returns with disciplined trading approaches - Jammu Links News
Should I hold or sell Adicet Bio Inc. stock in 2025Unmatched profit potential - Jammu Links News
What is the risk reward ratio of investing in Adicet Bio Inc. stockFree Consultation - Jammu Links News
How does Adicet Bio Inc. compare to its industry peersFastest-growing stock picks - Jammu Links News
What institutional investors are buying Adicet Bio Inc. stockNavigate the market with precision tools - Jammu Links News
Is Adicet Bio Inc. stock overvalued or undervaluedBuild wealth with steady, reliable stocks - Jammu Links News
When is Adicet Bio Inc. stock expected to show significant growthFastest return on investment - Jammu Links News
How does Adicet Bio Inc. generate profit in a changing economyMarket-crushing profits - Jammu Links News
What are the technical indicators suggesting about Adicet Bio Inc.Track top-performing stocks effortlessly - Jammu Links News
What makes Adicet Bio Inc. stock price move sharplyUnprecedented profits - Jammu Links News
Building trade automation scripts for Adicet Bio Inc.Low Exposure Strategy with Sector Analysis - Newser
How high can Adicet Bio Inc. stock price go in 2025Free Daily Momentum Screener With Alerts - Newser
Tools to monitor Adicet Bio Inc. recovery probabilityPattern Recognition Tool for ROI Investors - Newser
Sentiment analysis tools applied to Adicet Bio Inc.AI Enhanced Strategy for Portfolio Growth - Newser
Pattern recognition hints at Adicet Bio Inc. upsideBreakout Screener With Alert Based Timing - Newser
Custom watchlist performance reports with Adicet Bio Inc.Predictable Return Plan with Entry Guidance - Newser
Advanced analytics toolkit walkthrough for Adicet Bio Inc.Market Sentiment Tracker with Smart Alerts - Newser
How Adicet Bio Inc. stock performs during market volatilityInvestment Roadmap for High Potential Stocks - Newser
Adicet Bio Inc. stock trend outlook and recovery pathTrading Volume Spike and Reversal Analysis - Newser
Why Adicet Bio Inc. stock attracts strong analyst attentionExit Ready Momentum Stock Watchlist Expanded - beatles.ru
Adicet Bio Inc Stock (ACET) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
3.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):